Results:
In vitro allogeneic stimulation of CD8 + T cells resulted in OX40 expression, the blockade of which was found to partially inhibit proliferation. Similarly, in vivo, anti-OX40
prevented skin allograft rejection mediated by CD8 + T cells. However, following cessation of anti-OX40 therapy, skin allografts were eventually rejected indicating that tolerance had not been induced. Surprisingly, analysis of lymph nodes draining skin allografts, revealed that OX40 blockade had no effect on the activation and proliferation of BM3 T cells but rather resulted in diminished effector T cell accumulation.
Conclusion:
Taken together, these data demonstrate that anti-OX40 attenuates CD8 + T cell responses to alloantigen by reducing the pool of effector T cells and suggests that this may be a worthwhile adjunct to pre-existing costimulatory molecule blocking regimens.
INTRODUCTION
Naïve T cells undergo differentiation and clonal expansion following recognition of foreign antigen. T cell activation results from the ligation of the T cell receptor (TCR) following interaction with major histocompatability complex (MHC) and peptide complexes (signal 1).
However, whilst providing the specificity of the response this signal alone is not sufficient to drive productive T cell responses and a second signal is required between accessory molecules, which has been termed costimulation. OX40 (CD134) is a 50kDa is a transmembrane protein belonging to the tumour necrosis factor receptor (TNFR) superfamily which has been shown to possess costimulatory properties (1 Figure 1A ). However, after stimulation, OX40 was upregulated by the third day of culture on both BM3 and polyclonal CD8 + T cells with maximal OX40 expression found on day 5 on both CD8 + T cells populations ( Figure 1A) .
The kinetics and level of OX40 expression was comparable in both populations ( Figure 1B ).
Anti-OX40 Fab PEG partially inhibits the proliferation of alloreactive CD8 + T cells.
As both BM3 and polyclonal CD8 + T cell populations exhibited comparable expression and kinetics of OX40, BM3 CD8 + T cells were used to determine whether blocking the OX40-OX40L pathway, by means of anti-OX40 Fab PEG, had an effect on proliferation to alloantigen, measured by 3 H-thymidine incorporation. A dose response curve was generated to determine the concentration of anti-OX40 Fab PEG that gave maximal inhibition of proliferation to alloantigen in vitro. Anti-OX40 Fab PEG partially inhibited the proliferation response when pulsed with 3 H-thymidine on day 4 and harvested 18 hours later with a maximum (74%) inhibition at 10µg/ml compared to PEGylated Fab control ( Figure 2A ).
Given that OX40 has been implicated in the effector and memory stages rather than the initiation phase of the immune response (11), the ability of anti-OX40 Fab PEG to inhibit proliferation was tested at various time-points following stimulation ( Figure 2B ). However, Finally, we analysed mice at different times after transplantation as following cessation of anti-OX40 therapy all skin allografts were eventually rejected. Consistent with the survival data ( Figure 3 ), anti-OX40 Fab PEG inhibited the accumulation of the BM3 CD8 + T cells at day 10 post transplantation ( Figure 4C ), but by 10 days after the anti-OX40 Fab PEG administration was stopped (i.e. day 38) BM3 CD8 + T cells were found to have accumulated specifically in the dLN pre-empting rejection. By day 100 post transplantation no difference in BM3 CD8 + T cell number was seen between mice that had received anti-OX40 Fab PEG and those that had received the PEGylated Fab control ( Figure 4C ).
DISCUSSION
A battery of costimulatory molecules have now been identified that contribute to the activation, proliferation and survival of CD4 + and CD8 + T cells. However, studies using genetically modified mice and monoclonal antibody mediated blockade have demonstrated that there is significant overlap in function, and therefore redundancy, amongst costimulatory pathways (24) suggesting that the involvement of distinct costimulatory pathways may depend on temporal or spatial differences between responses. Given the importance of costimulation to T cell response to antigen, blockade of these molecular interactions holds much promise as a therapy for inducing tolerance to alloantigen after transplantation.
Undoubtedly CD28/CD80/CD86 and CD40/CD154 interactions are the most important forms of costimulation for initial T cell activation and proliferation. Furthermore, blockade of these pathways, either alone or in combination, has been shown to prolong allograft survival or in some cases has led to long term survival of the allografts in rodents (25) (26) (27) (28) and in nonhuman primates (29) . However, blockade of CD28 and CD154 molecules rarely leads to the induction of tolerance to allografts, which may be due in part to the presence of CD154/CD28 independent CD8 + T cells (30) . Therefore, the identification and targeting of other costimulatory pathways that may be utilised by CD8 + T cells responding to allografts may be a beneficial adjunct to such potential therapies.
More recently alternative costimulatory molecules have been described, including OX40 and OX40L which are members of the TNF and TNFR superfamilies, respectively, and have been identified as important T cell costimulatory molecules (12, 31, 32) . OX40 + T cells have been associated with a number of autoimmune diseases, in both rodent models and in the clinic (20) (21) (22) (33) (34) (35) (36) .
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After engagement of the TCR with MHC-peptide complex on the APC, OX40 is upregulated on the surface of the T cell. Our data shows OX40 expression on CD8 + T cells (transgenic or polyclonal) is not expressed until 48 hours after activation, with maximal levels observed 5 days after stimulation (Figure 1 ). This is in agreement with the proposed role of OX40, i.e. in the propagation of the response, rather than in the priming and initiation phase. 
Surgical Procedures
Full thickness tail skin (1cm 2 ) was transplanted onto the left flank of CBA RAG -/ -recipient mice one day after adoptive transfer of cells as previously described (44) . Grafts were covered with sterile dressings for 7 days and graft viability was assessed daily. Rejection was defined as complete loss of viable donor skin. 
Antibody treatment in vivo

CFSE labelling
Leukocyte cell suspensions were incubated for 10 minutes with 5µM of 5-and 6-carboxyfluorescein diacetate, succinimidyl ester (CFSE; Molecular Probes Inc, Netherlands).
Cells were washed in ice-cold RPMI 1640 (Invitrogen Life Technologies) then resuspended in PBS (Oxoid, Oxford) prior to adoptive transfer.
Flow cytometry analysis
Leukocytes isolated from spleen or lymph nodes were stained with anti-CD3-PE-Cy7 (145-2C11) (eBioscience), anti-CD8-APC (53-6.7) (eBioscience), anti-clonotypic TCR-biotin (Ti98) and anti-OX40-PE (OX86) (eBioscience). After washing, each sample was incubated with streptavidin-APC Cy7 (eBioscience). The absolute number of BM3 CD8 + T cells was determined using synthetic fluorescent beads (CaliBRITE beads, BD Biosciences) as described previously (23) . The samples were analysed with a FACSCanto flow cytometer (BD Immunocytometry systems). Fab PEG or PEGylated Fab control was added to the appropriate wells at 10µg/ml unless stated otherwise.
Mixed lymphocyte Reaction
Statistical Analysis
Data were analysed using the Student's t-test using Prism (version 3; Graph Pad software) and are expressed as mean ± standard deviation (SD). Kaplan-Meier survival graphs were constructed and log rank comparisons of the groups were used to calculate P values. Values for p < 0.05 were considered statistically significant.
